{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Revefenacin",
    "query": {
      "intervention": "Revefenacin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Revefenacin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T18:05:36.138Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07721922",
      "title": "Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD Exacerbation"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "formoterol fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Sterile Normal Saline)",
          "type": "OTHER"
        },
        {
          "name": "Albuterol sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium Bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2026-09-01",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07721922"
    },
    {
      "nct_id": "NCT07133880",
      "title": "Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD (Chronic Obstructive Pulmonary Disease)"
      ],
      "interventions": [
        {
          "name": "umeclidinium 62.5 µg and vilanterol 25 µg",
          "type": "DRUG"
        },
        {
          "name": "Revefenacin 175 µg, Formoterol 20 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo ( Revefenacin and Formoterol )",
          "type": "DRUG"
        },
        {
          "name": "Placebo DPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2023-12-05",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07133880"
    },
    {
      "nct_id": "NCT02512510",
      "title": "Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "TD-4208",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 611,
      "start_date": "2015-09",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Easley, South Carolina",
      "locations": [
        {
          "city": "Easley",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02512510"
    },
    {
      "nct_id": "NCT03095456",
      "title": "Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease, COPD",
        "Low Peak Inspiratory Flow Rate (PIFR)"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "Spiriva Handihaler®",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo for Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Spiriva Handihaler®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2017-03-27",
      "completion_date": "2017-11-25",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Rock Hill, South Carolina",
      "locations": [
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03095456"
    },
    {
      "nct_id": "NCT05165485",
      "title": "Phase 4 COPD and Suboptimal Inspiratory Flow Rate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Revefenacin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravance Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 404,
      "start_date": "2022-01-07",
      "completion_date": "2023-11-20",
      "has_results": true,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 76,
      "location_summary": "Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05165485"
    },
    {
      "nct_id": "NCT04655170",
      "title": "Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD Exacerbation"
      ],
      "interventions": [
        {
          "name": "Revefenacin (YUPELRI) & Formoterol (Perforomist)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-12-09",
      "completion_date": "2023-06-01",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04655170"
    },
    {
      "nct_id": "NCT04315558",
      "title": "Revefenacin in Acute Respiratory Insufficiency in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD",
        "Acute Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "Revefenacin Inhalation Solution [Yupelri]",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium Bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-11-01",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Santa Monica, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04315558"
    },
    {
      "nct_id": "NCT02518139",
      "title": "A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "TD-4208",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1060,
      "start_date": "2015-09",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Easley, South Carolina",
      "locations": [
        {
          "city": "Easley",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518139"
    },
    {
      "nct_id": "NCT03573817",
      "title": "A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Formoterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2018-05-31",
      "completion_date": "2018-09-25",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 12,
      "location_summary": "Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03573817"
    },
    {
      "nct_id": "NCT02581592",
      "title": "Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "TD-4208",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 16,
      "start_date": "2015-11",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-02T18:05:36.138Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581592"
    }
  ]
}